JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online June 12, 2009, 10.2967/jnumed.109.062208
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brepoels, L.
Right arrow Articles by De Wolf-Peeters, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brepoels, L.
Right arrow Articles by De Wolf-Peeters, C.

18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model

Lieselot Brepoels1,2, Sigrid Stroobants1,2, Gregor Verhoef3, Tjibbe De Groot2,4, Luc Mortelmans1,2 and Christiane De Wolf-Peeters5

1 Department of Nuclear Medicine, University Hospital Gasthuisberg Leuven, Leuven, Belgium; 2 Molecular Small Animal Imaging Centre, University Hospital Gasthuisberg Leuven, Leuven, Belgium; 3 Department of Hematology, University Hospital Gasthuisberg Leuven, Leuven, Belgium; 4 Laboratory for Radiopharmacy, University Hospital Gasthuisberg Leuven, Leuven, Belgium; and 5 Department of Pathology, University Hospital Gasthuisberg Leuven, Leuven, Belgium


Figure 1
View larger version (70K):
[in this window]
[in a new window]

  		FIGURE 1.  Example of serial small-animal PET images on D0 and on D+1, D+2, D+4, D+7, D+9, D+11, and D+14 after treatment with cyclophosphamide as measured with 18F-FDG (A) and 18F-FLT (B) PET.

 

Figure 2
View larger version (11K):
[in this window]
[in a new window]

  		FIGURE 2.  18F-FDG and 18F-FLT uptake as measured by serial small-animal PET and expressed as mean SUVFDG and mean SUVFLT ± SEM in mice treated with cyclophosphamide (A), compared with mice treated with temsirolimus (B). Blue curve = percentage decrease in SUVFDG; red curve = SUVFLT. *Significant at the P ≤ 0.05 level.

 

Figure 3
View larger version (79K):
[in this window]
[in a new window]

  		FIGURE 3.  Example of serial small-animal PET images on D0 and on D+1, D+2, D+4, D+7, D+9, D+11, and D+14 after treatment with temsirolimus and measured with 18F-FDG (A) and 18F-FLT (B) PET.

 

Figure 4
View larger version (96K):
[in this window]
[in a new window]

  		FIGURE 4.  Immunohistochemical staining for cyclin D1 at day 0 (before) and at D+2 and D+7 after treatment. Staining for cyclin D1 shows moderate decrease in cyclin D1–positive tumor cells after 2 d of treatment with cyclophosphamide. After administration of temsirolimus, important decrease in amount of cyclin D1–positive tumor cells was seen at D+2, which increased again on day 7.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.